- Neuroendocrine Cancer
- Newly Diagnosed
- Carcinoid & Neuroendocrine Tumor Patient Community
- Doctor Database
- Clinical Trials
- Educational Resources
- Additional Resources
- Join Us For a Cure
- Researching Funding Opportunities
- Current Research Grants
- Previous Research Grants
- Research Approach
- Board of Scientific Advisors
- About Us
- CFCF News
- Founder Nancy Lindholm
- Corporate Sponsorship
Monday, February 4, 2013
2012 was a year of great progress and connection and I am extremely grateful to so many of you for sharing your time, your energy and your perspectives with me. It has been a particular joy and privilege to work with you and I look forward to continuing our work together in 2013.
Among the highlights:
Progress in Research supporting and expanding an active community of top researchers and labs committed to NET cancer research. “The generous support of our individual donors and private foundation supporters is what fuels this process and enables CFCF to attract top investigators to the cause.” In 2012, CFCF:
The "Fiscal Cliff" and NET: Threats to Rare Disease Programs; Private Support of NET Research More Important Than Ever
Wednesday, November 28, 2012
As you no doubt have been hearing ever since the election, all eyes are on Washington and the current negotiations attempting to avoid the so-called “fiscal cliff”. While the headlines focus primarily on the prospects for tax increases and potential cuts to entitlement programs, should the negotiations fail, all rare disease organizations are deeply concerned about the impact on research and FDA programs. These budget cuts that will go into effect for NIH, FDA and other government agencies on January 1 if Congress does not take action to resolve the budget impasse.
Thursday, October 25, 2012
Over the past few months I have had the privilege of speaking to so many of you: patients and family members touched by NET cancer, researchers who are committed to finding the causes and developing new treatments, and clinical leaders dedicated to applying the latest tools for eliminating the suffering.
The “Journey”: Living with carcinoid/NET Cancer
At the heart of all of these conversations is the frustration that far too many patients experience as they deal with late diagnosis, misdiagnosis, and as a result, significant metastatic disease. They also often face complex and confusing treatment choices and inconsistent access to the clinical expertise and experience in NET that makes such a difference when living with the disease. Many of you refer to this as the “journey”.
Friday, April 20, 2012
Greetings to all. I wanted to share my excitement with you after an exciting day on the research front.
On April 11, CFCF co-hosted, along with our partner, the Raymond and Beverly Sackler Foundation for the Arts and Sciences, our annual Research Symposium at the Whitehead Institute for Biomedical Research here in Cambridge, Massachusetts. This meeting brings together leading researchers and labs focused on carcinoid and neuroendocrine tumors (C/NET) from around the country and around the world.
The Symposium was followed by a meeting of our CFCF Board of Scientific Advisors (BOSA). This is where leading scientists committed to our goals review progress reports and consider exciting new developments funded by CFCF.
Monday, February 27, 2012
I am thrilled to have the opportunity to communicate with you for the first time through this blog and look forward to our exciting work together.
I have been at the Caring for Carcinoid Foundation for just a month now, and am incredibly impressed at the energy and commitment that the Board, our staff, our researchers, and volunteers bring to our core mission of finding cures for carcinoid and related neuroendocrine cancers and supporting the patients, families and friends affected by these conditions.
There is so much positive momentum. The research we sponsor with your generous donations continues to yield breakthrough results. Just last week, a CFCF sponsored study was featured in the prestigious journal Nature.